Tecentriq could be first front-line SCLC therapy approved in two decades

FDA accepted and granted Priority Review to an sBLA from Genentech Inc. for anti-PD-L1 mAb Tecentriq atezolizumab as first-line treatment of extensive-stage small cell lung cancer. Its PDUFA date is March 18, 2019.